Suchergebnisse - "Antiviral Agents"

PubPharm (183)

1

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B : a systematic review and meta-analysis of individual participant data

enthalten in: Antiviral therapy | 2019

von Pavlovic, V. | Yang, L. | Chan, H. | +10

2

A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells

enthalten in: Antiviral therapy | 2018

von Beesetti, H. | Tyagi, P. | Medapi, B. | +4

3

RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B

enthalten in: Antiviral therapy | 2018

von Wu, S. | Lin, J. | Fu, Y. | +1

4

Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients : a pilot study

enthalten in: Antiviral therapy | 2018

von Tatsukawa, Y. | Tsuge, M. | Kawakami, Y. | +16

ErratumIn: Antivir Ther. 2019;23(8):709. - PMID 30632982

5

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B

enthalten in: Antiviral therapy | 2018

von Hagiwara, S. | Nishida, N. | Watanabe, T. | +8

6

An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings

enthalten in: Antiviral therapy | 2018

von Lampertico, P. | Messinger, D. | Oladipupo, H. | +3

7

Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B

enthalten in: Antiviral therapy | 2017

von Limothai, U. | Chuaypen, N. | Khlaiphuengsin, A. | +3

8

Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a : 1 year follow-up of the OSST study

enthalten in: Antiviral therapy | 2016

von Han, M. | Jiang, J. | Hou, J. | +4

9

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection : the ATAHC II and DARE-C I studies

enthalten in: Antiviral therapy | 2016

von Martinello, M. | Hellard, M. | Shaw, D. | +12

10

Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB

enthalten in: Antiviral therapy | 2015

von Yan, W. | Wu, D. | Wang, X. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[19]